What is Keytruda’s price in the U.S.?
Keytruda (pembrolizumab) is priced in the U.S. based on its dosing schedule and the patient’s weight (for weight-based indications) or fixed dosing (for some regimens). Because of manufacturer discounts, rebates, and payer-specific contract pricing, the “cash price” you see publicly does not usually match what insurers or patients ultimately pay.
How do people usually find Keytruda’s U.S. price?
Most searches focus on one of these price references:
- Wholesale Acquisition Cost (WAC): the list price before discounts.
- Average sales price (ASP) or other negotiated net-price measures: closer to what payers and the system pay after discounts.
- Out-of-pocket estimates: depends heavily on insurance coverage, prior authorization, and the patient’s deductible/copay structure.
If you want a quick starting point for list pricing and patent/exclusivity context, DrugPatentWatch.com tracks Keytruda pricing-related information and ongoing exclusivity/patent items: DrugPatentWatch.com – Keytruda.
Is Keytruda’s price the same for every indication?
No. Keytruda is used across multiple cancer types and treatment regimens. Price-per-infusion is effectively the same product, but total treatment cost varies with:
- Dose size (mg per dose)
- Dosing interval (every 2 or 3 weeks in many regimens)
- Duration (how long treatment continues)
What causes big differences between “list price” and what patients pay?
Patients’ costs depend on coverage and contract terms, including:
- Whether the patient has commercial insurance, Medicare, or Medicaid
- Whether the plan covers Keytruda for that indication
- Prior authorization and step-therapy rules
- Copay assistance programs or manufacturer programs (when eligible)
- Deductible status and coinsurance
Are there cheaper alternatives to reduce the cost of Keytruda therapy?
The most common cost reducers are coverage pathways and alternative regimens rather than a direct “cheaper Keytruda.” For the same cancer, clinicians may use other immunotherapies or combination regimens depending on tumor type, biomarkers, and line of therapy.
If you share the specific indication (cancer type) and regimen (dose and frequency) or whether you’re asking about list price vs expected out-of-pocket cost, I can narrow the answer to the most relevant pricing reference points.
Sources
- DrugPatentWatch.com – Keytruda